FUSIONPHARM offers guaranteed financing to licensed cannabis
industry operators
DENVER, May
14, 2013 /PRNewswire/ -- FusionPharm, Inc. (OTC: FSPM),
the developer of the patent pending PharmPods™ hydroponic
cultivation system (www.pharmpods.com), today announced that it
will immediately begin offering guaranteed financing to state
licensed cannabis cultivators via its licensee, Colorado based Meadpoint Venture Partners.
PharmPod containers utilize state of the art lighting systems,
super-efficient HVAC systems and automated control systems to
achieve outstanding results in controlled environment
agriculture.
"Given the problems with banking and traditional capital sources
in the cannabis industry, we realize that providing financing to
licensed cultivators will allow us to maximize our sales
potential," said FusionPharm CEO Scott
Dittman. "We expect sales of our container systems in
the cannabis space to increase substantially with the availability
of financing and the growth of the cannabis industry in our home
state of Colorado and the many
other States that will soon issue cultivation permits."
About FusionPharm, Inc.
FusionPharm, Inc. was organized to capitalize on opportunities
present in the rapidly growing organic/local food and cannabis
industries. FusionPharm's primary focus is the development and
deployment of the patent pending PharmPods(TM) advanced hydroponic
cultivation systems. PharmPods are constructed from standard ISO
steel shipping containers that are repurposed for use in indoor
controlled environment agriculture. Using advanced lighting
technology, cutting edge growing media and proprietary cultivation
techniques, a single PharmPod is capable of growing more produce
than one full acre of traditional agriculture in less than half the
time using 90% less water than traditional agriculture, with no
harmful pesticides or herbicides.
NOTES ABOUT FORWARD-LOOKING STATEMENTS: Except for any
historical information contained herein, the matters discussed in
this press release contain forward-looking statements that involve
risks and uncertainties, including those described in the Company's
Securities and Exchange Commission reports and filings. Certain
statements contained in this release that are not historical facts
constitute forward-looking statements, within the meaning of the
Private Securities Litigation Reform Act of 1995, and are intended
to be covered by the safe harbors created by that Act. Reliance
should not be placed on forward-looking statements because they
involve unknown risks, uncertainties and other factors, which may
cause actual results, performance or achievements to differ
materially from those expressed or implied. Forward-looking
statements may be identified by words such as estimates,
anticipates, projects, plans, expects, intends, believes, should
and similar expressions and by the context in which they are used.
Such statements are based upon current expectations of the Company
and speak only as of the date made. The Company undertakes no
obligation to update any forward-looking statements to reflect
events or circumstances after the date on which they are made.
Contact: FusionPharm, Inc.
info@fusionpharminc.com
SOURCE FusionPharm, Inc.